![]() |
![]() |
FDA Home Page | Search FDA Site | FDA A-Z Index | Contact FDA
![]()
| Center | Date | Time | Location |
|---|---|---|---|
| CDRH | July 15, 2005 | 8:30 a.m. - 5:00 p.m. | Holiday Inn |
Agenda:
The committee will hear a presentation on the FDA Critical Path Initiative and
a presentation by the Office of Surveillance and Biometrics in the Center for
Devices and Radiological Health outlining their responsibility for the review
of postmarket study design. The committee will also discuss, make recommendations,
and vote on a premarket approval application for a laboratory assay designed
to measure levels of neural thread protein in urine specimens from patients
presenting with cognitive complaints or other signs and symptoms of suspected
Alzheimer’s disease. Results from this test are intended for use, in conjunction
with and not in lieu of current standard diagnostic procedures, to aid the physician
in the differential diagnosis of Alzheimer’s disease.
Background material and meeting information will become available no later than one business day before the meeting (Simply scroll down to the appropriate committee heading).
Procedure:
Interested persons may present data, information, or views, orally or in writing,
on issues pending before the committee. Written submissions may be made to the
contact person by July 1, 2005. Oral presentations from the public will be scheduled
for approximately 30 minutes at the beginning of committee deliberations and
for approximately 30 minutes near the end of the deliberations. Time allotted
for each presentation may be limited. Those desiring to make formal oral presentations
should notify the contact person before July 1, 2005, and submit a brief statement
of the general nature of the evidence or arguments they wish to present, the
names and addresses of proposed participants, and an indication of the approximate
time requested to make their presentation. Persons attending FDA's advisory
committee meetings are advised that the agency is not responsible for providing
access to electrical outlets.
FDA welcomes the attendance of the public at its advisory committee meetings
and will make every effort to accommodate persons with physical disabilities
or special needs. If you require special accommodations due to a disability,
please contact Shirley Meeks, Conference Management Staff, at 240–276–0450,
ext. 105, at least 7 days in advance of the meeting.
Contact Person:
Rufina Carlos, Center for Devices and Radiological Health (HFZ–440), Food
and Drug Administration, 2098 Gaither Rd., Rockville, MD 20850, 240–276–0493,
ext. 167.
Advisory Committee Telephone Information Line:
Please call the Information Line for up-to-date information on this
meeting, 1-800-741-8138 (301-443-0572 in the Washington, DC area), code 3014512516.
![]()